Navigation Links
CV Therapeutics Reports 2008 Third Quarter Financial Results
Date:11/6/2008

- Ranexa(R) net revenue grows 19 percent quarter-over-quarter -

PALO ALTO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today reported financial results for the third quarter ended September 30, 2008.

For the quarter ended September 30, 2008, the Company reported a net loss of $25.4 million, or $0.41 per share. This compares to a net loss of $34.2 million, or $0.58 per share, for the same quarter in 2007 and $4.3 million, or $0.07 per share, for the prior quarter ended June 30, 2008. Excluding the impact of the $22.0 million milestone revenue recognized in the quarter ended June 30, 2008, the prior quarter net loss would have been $26.3 million. The milestone payments received in the second quarter of 2008 were $12.0 million from Astellas Pharma U.S. Inc. (Astellas) associated with the U.S. Food and Drug Administration approval for Lexiscan(R) (regadenoson) injection and $10.0 million relating to a milestone payment from TPG-Axon Capital associated with the commercial launch of Lexiscan(R).

For the quarter ended September 30, 2008, the Company recorded $30.3 million of net product sales of Ranexa(R) (ranolazine extended-release tablets) in the U.S., which represents an increase of 19 percent compared to the $25.4 million of net product sales recorded in the prior quarter ended June 30, 2008 and an increase of 65 percent compared to the $18.4 million of net product sales recorded in the same quarter in the prior year.

For the quarter ended September 30, 2008, the Company recorded total revenues of $38.1 million, which consisted of $30.3 million of net product sales of Ranexa, $4.7 million of royalty and license revenue and $3.2 million of collaboration, milestone and other reve
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
2. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
3. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
4. Nile Therapeutics to Present at Two Upcoming Investor Conferences
5. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
6. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. United Therapeutics Reports Third Quarter 2008 Financial Results
9. Arete Therapeutics Bolsters Management Team
10. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
11. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Physicians ... its cardiovascular pharmacogenetics menu, which enables healthcare providers ... With PCLS’s evidence-based results, healthcare providers are ... optimize their therapy, while minimizing risks for adverse ... U.S., according to the FDA [1] more than ...
(Date:10/22/2014)... 22, 2014 Research and Markets  has ... by Material, by Application, Geography - Global Analysis and ... Organic electronics, also called as polymer ... science which deals with small conductive molecules and electrically ... molecules and polymers are carbon based, made using synthetic ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias Biotherapeutics, ... Company has signed a Notice of Grant Award ... (CIRM), effective October 1, 2014.  The NGA provides ... and the release of additional grant funds pursuant ... award for clinical development of Asterias, product, AST-OPC1. ...
(Date:10/20/2014)... OncLive® is pleased to ... Thomas Jefferson University has joined its Strategic Alliance ... Partnership program, the Sidney Kimmel Cancer Center at ... of the Center’s cutting-edge research programs, comprehensive approach ... other health care professionals from the Sidney Kimmel ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... /PRNewswire-FirstCall/,-- Oridion Systems Ltd. (SWX: ORIDN) today ... leading global medical device and service company.,With ... technology in its new, compact and ultra-lightweight ... the importance of monitoring CO2, has,decided to ...
... $2.0 Million -, MONTVALE, N.J., Aug. 26 ... it has secured,$2.0 million through the sale of approximately ... under its June 2007 equity financing agreement,with an investment ... Pharmaceuticals exercised its option to complete the third,and final ...
... Calif., Aug. 26 The 2008 European ... presented to,Israel-based Vascular Biogenics Ltd. for developing ... has facilitated novel advancements,in gene expression-based treatments ... VTS(TM) platform is a potent and flexible ...
Cached Biology Technology:Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 2Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 3Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 4Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute 2Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute 3Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award 2Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award 3
(Date:10/18/2014)... stress-related psychiatric disorders are associated with increased ... mechanisms underlying this relation are unknown. Understanding ... of targeted preventive strategies and new or ... work is presented at the European College ... international group of researchers from Germany and ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Sperm wars 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3
... Invasive species plants, animals, and microbes introduced to regions ... tag of $1.4 trillion dollars . They are responsible for ... and an uptick in infectious diseases. Not all non-native ... the last several decades teasing apart the conditions that set ...
... 2012 In forested regions of the nation, natural regeneration ... of maintaining the desired tree species. , A study by ... and Urban Greening showed that on average, 1 in ... from natural regeneration. However, for newly established, young trees in ...
... , When you take a dip in the ocean, nuclear fuel ... Earths oceans in trace amounts of just 3 parts per billion, ... billion tons of uranium enough to potentially fuel the worlds ... the ocean as a uranium source since the 1960s, but previous ...
Cached Biology News:Losing stream in our battle to predict and prevent invasive species 2Losing stream in our battle to predict and prevent invasive species 3Natural regeneration building urban forests, altering species composition 2Natural regeneration building urban forests, altering species composition 3
... Dodeca silver stain kits are optimized ... including Bio-Rad Dodeca stainers. This silver ... of proteins in polyacrylamide gels and ... includes sensitizer concentrate, silver reagent concentrate, ...
... tubes and 96 well plates. microCLEAN is an ... a half spin DNA cleanup reagent. It can ... type of double stranded DNA, efficiently removing reaction ... or unlabelled). It is therefore ideally suited to ...
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
... (bluish-purple), DNA (blue), proteins (red) and acid polysaccharides ... traces: Ca ≤ 10 mg/kg Cd ≤ 5 mg/kg ... ≤ 5 mg/kg Fe ≤ 5 mg/kg K ≤ ... mg/kg Na ≤ 50 mg/kg Ni ≤ 5 mg/kg ...
Biology Products: